NOVEL MECHANISMS FOR ACTION OF EXTREMAL AGENTS: THE ROLE OF TRANSFORMING GROWTH FACTOR TYPE BETA
DOI: http://dx.doi.org/10.30970/sbi.0201.009
Abstract
The article summarizes the results obtained during the last years at the Department headed by the article author, as well as literature data, on the role of transforming growth factor type beta in the action towards animal and human organisms of extremal agents of different nature – chemical, physical, mechanical, pathobiological. It is demonstrated that those agents can stimulate the mammalian cells to production of that cytokine which acts as growth inhibitor and apoptosis inducer for cells of epithelial origin and for most immunocompetent cells. The mechanisms used by tumor cells to achieve their resistance to the effect of this cytokine, that can help them to escape of its inhibitory action, are described.
Keywords
Full Text:
PDF (Українська)References
1. Англо-Український ілюстрований медичний словник Дорланда (у 2-х томах). Львів: Наутілус, 2002. Т. 2. С. 2213. | |
| |
2. Кусень С.И., Стойка Р.С. Молекулярные механизмы в действии полипептидных факторов роста. Москва: Наука, 1985. 234 с. | |
| |
3. Фильченков А.А., Стойка Р.С., Быкорез А.И. Трансформирующие факторы роста. Киев: Наукова думка, 1994. 290 с. | |
| |
4. Souchelnytskyi S. Transforming growth factor-β signaling and its role in cancer. Exp. Oncol, 2002; 24(1): 3-12. | |
| |
5. Фильченков А.А., Стойка Р.С. Апоптоз і рак: від теорії до практики. Тернопіль: Укрмедкнига, 2006. 524 с. | |
| |
6. De Larco J.E., Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc. Nat. Acad. Sci. USA, 1978; 75(8): 4001-4005. | |
| |
7. Cui W., Akhurst R. Transforming growth factor bs: Biochemistry and biological activities in vitro and in vivo. In: Growth factors and cytokines in health and disease. N.Y.: JAI Press, 1996. P.309-356. | |
| |
8. Massague J. TGF-β signal transduction. Annu. Rev. Biochem, 1998; 67: 753-791. | |
| |
9. Derynck R., Zhang Y., Feng X.-H. Smads: transcriptional activators of TGF-β responses. Cell. 1998; 95(4): 737-740. | |
| |
10. Miyazono K., ten Dijke P., Heldin C.-H. TGF-beta signaling by Smad proteins. Adv. Immunol, 2000; 75: 115-157. | |
| |
11. Itoh S., Itoh F., Goumans M.J., ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur. J. Biochem, 2000; 267(24): 6954-6967. | |
| |
12. Mulder K.M. Role of Ras and Mapks in TGFbeta signaling. Cytokine and Growth Factor Review, 2000; 11(1-2): P.23-35. | |
| |
13. Glick A.B., Lee M.M., Darwiche N. et al. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev, 1994; 8(20): 2429-2440. | |
| |
14. Yin J.J., Selander K., Chirgwin J.M. et al. TGF-β signaling blockade inhibits PHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest, 1999; 103(2): 197-206. | |
| |
15. Hanahan D., Weinberg R. The hallmarks of cancer. Cell, 2000; 100(1): 57-70. | |
| |
16. Torre-Amione G., Beauchamp R.D., Koeppen H. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type b1 cDNA escapes immune surveillance. Proc. Nat. Acad. Sci. USA, 1990; 87(4): 1486-1490. | |
| |
17. Kehrl J.H., Roberts A.B., Wakefield L.M. et al. Transforming growth factor beta is an important immunomodulatroy protein for human B lymphocytes. J. Immunol, 1986; 137(12): 3855-3860. | |
| |
18. Arteaga C.L., Hurd S.D., Winnier A.R. et al. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implication for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest, 1993; 92(6): 2569-2576. | |
| |
19. Wrann M., Bodmer S., de Martin R. et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kD protein closely related to transforming growth factor-beta. EMBO J, 1987; 6(6): 1633-1636. | |
| |
20. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature, 1988; 334(6179): 260-262. | |
| |
21. Geiser A.G., Letterio J.J., Kulkarni A.B. et al. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-b1 null mouse phenotype. Proc. Nat. Acad. Sci. USA, 1993; 90(21): 9944-9948. | |
| |
22. Oft M., Heider K.H., Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol, 1998; 8(23): 1243-1252. | |
| |
23. Schesinger M.J. Heat shock proteins. J. Biol. Chem, 1990; 265(21): 12111-12114. | |
| |
24. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-β. Annu. Rev. Immunol, 1998; 10: 137-161. | |
| |
25. Zhang Y.W., Akman H.O., Smith E.L. et al. Cellular response to hypoxia involves signaling via Smad proteins. Blood, 2003; 101(6): 2253-2260. | |
| |
26. Marwick J.A., Kirkham P., Gilmour P.S. et al. Cigarette smoke-induced oxidative stress and TGF-beta1 increase of p21Waf1/cip1 expression in alveolar epithelial cells. Ann.N.Y. Acad. Sci, 2002; 973: 278-283. | |
| |
27. Nakatani T., Marui T., Hitora T. et al. Mechanical stretching force promotes collagen synthesis by cultured cells from human ligamentum flavum via transforming growth factor-beta 1. J. Orthoped. Res, 2002; 20(6): 1380-1386. | |
| |
28. Galvan V., Loginova A., Sperandio S. et al. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK 1). J. Biol. Chem, 2003; 278(15): 13325-13332. | |
| |
29. Stoika R.S., Yakymovych I.A., Antonenko S.V. et al. Transforming activity of growth factors in blood serum of AIDS and Kaposhi sarcoma patients. Эксп. Онкол, 1995; 17(1): 3-9. | |
| |
30. Жильчук В.Є., Воронова А.Л., Ключівська О.Ю. та ін. Прогностичне значення рівня ТФР-бета в сироватці крові хворих на рак молочної залози в умовах інтерферонотерапії. Онкологія, 2008. | |
| |
31. Стойка Р.С., Кусень С.И. Трансформирующий фактор роста β - новый тип ингибитора пролиферации нормальных и опухолевых клеток. Мол. Биол, 1990; 24(4): 73-76. | |
| |
32. Pasche B. Role of transforming growth factor beta in cancer. J. Cell. Physiol, 2001; 186(2): 153-168. | |
| |
33. Філяк Є.З., Філяк О.С., Стойка Р.С. Вплив протипухлинних препаратів на експресію компонентів сигнального шляху трансформуючого фактора росту бета у клітинах лінії А549 карциноми легень людини. Вісник Львівського університету. Серія біол. 2004; 35: 60-65. | |
| |
34. Stoika R., Yakymovych M., Yakymovych I., Souchelnitskiy S. Transforming growth factor b1 in tumor cell drug resistance. Acta Biochimica Polonica, 2003; 50(2): 497-508. | |
| |
35. Yakymovych M.Ya., Yakymovych I.A., Antonyuk V.O. et al. Lectins' cytotoxicity for L1210 murine leukemia cells with different sensitivity to anticancer drug cisplatin. Експ. і клін. фізіол. і біохім, 1999; 2: 39-45. | |
| |
36. Chorna I.V., Datsyuk L.O., Stoika R.S. Expression of Bax, Bad and Bcl-2 proteins under X-radiation effect towards human breast carcinoma MCF-7 cells and their doxorubicine-resistant derivatives. Эксп. Онкол, 2005; 27(3): 192-197. | |
| |
37. Stoika R.S., Korchinsky A.G., Kusen S.I. The effect of heat shock on the autocrine functions in tumour and normal cells. Эксп. Онкол, 1994; 16(4-6): 83-89. | |
| |
38. Стойка Р.С., Якимович І.А. , Кащак Н.І. та ін. Вплив протипухлинних препаратів на продукцію трансфофрмуючого фактора росту β та експресію білків р53 і Bcl-2 клітинами ліній MCF-7 і T47D карциноми молочної залози людини. Эксп. Онкол, 2008. | |
| |
39. Shyr-Ming Sheen-Chen, Han-Shiang Chen, Chih-Wei Sheen et al. Serum levels of transforming growth factor β1 in patients with breast cancer. Arch. Surg, 2001; 136(8): 937-940. | |
| |
40. Takanami I., Imamura T., Hashizume T. et al. Transforming growth factorbeta 1 as a prognostic factor in pulmonary adenocarcinoma. J. Clin. Pathol, 1994; 47: 1098-1100. | |
| |
41. Barthelemy-Brichant N., David J.L., Bosquée L. et al. Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms. Eur. J. Clin. Invest, 2002; 32 (3): 193-198. | |
| |
42. Wolff J.M., Fandel T., Borchers H. et al. Transforming growth factor-pi serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. Br. J. Urol, 1998; 81: 403-405. | |
| |
43. Ford J., Smith S., Luo J.C. et al. Serum growth factors and oncoproteins in firefighters. Occup Med (Lond), 1992; 42: 39-42. | |
| |
44. Teicher B.A. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev, 2001; 20: 133-143. | |
| |
45. Fridenberg, W.R., Salzman, S.A. et al. Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia. Med. Oncol, 1999; 16(2): 110-118. | |
| |
46. Bennett W.P., Deiry W.S., Rush W.L. et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin. Cancer Res, 1998; 4: 1499-1506. | |
| |
47. Boldrini L., Calcinai A., Samaritani E. et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma, putative relation with BCL-2-mediated neovascularization. Br. J. Cancer, 2000; 83: 480-486. | |
| |
48. Fisher J.R., Darjes H., Lahm H. et al. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur. J. Cancer, 1994; 30A: 2125-2129. | |
| |
49. Lagadec P.F., Saraya K.A., Balkwill F.R. Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int. J. Cancer, 1991; 48: 311-317. | |
| |
50. Tang B., de Castro K., Barnes H.E. et al. Loss of responsiveness to transforming growth factor beta induces malignant transformation of non-tumorigenic rat prostate epithelial cells. Cancer Res, 1999; 59(19): 4834-4842. | |
| |
51. Bottinger E.P., Jakubczak J.L., Haines D.C. et al. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhances tumorigenesis in the mammary gland and lung in response to the carcinohgen 7,12-dimethylnebz-[a]-anthracene. Cancer Res, 1997; 57(24): 5564-5570. | |
| |
52. Kanzler S., Meyer E., Lohse A.W. et al. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene, 2001; 20(36) 5015-5024. | |
| |
53. Engel J.D., Kundu S.D., Yang T. et al. Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology, 1999; 54(1): 164-170. | |
| |
54. Chen T., Yan W., Wells R.G. et al. Novel inactivating mutations of transforming growth factor-beta type I receptor in head-and-neck cancer metastases. Int. J. Cancer, 2001; 93(5): 653-661. | |
| |
55. Chen T., Carter D., Garrigue-Antar L., Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res, 1998; 58(21): 4805-4810. | |
| |
56. Goggins M., Shekher M., Turnacioglu K. et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res, 1998; 58(23): 5329-5332. | |
| |
57. Periyasamy S., Ammanamanchi S., Tillekeratne M.P., Brattain M.G. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency. Oncogene, 2000; 19(40) 4660-4667. | |
| |
58. Tokunaga H., Lee D.H., Kim I.Y. et al. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin. Cancer Res, 1999; 5(9): 2520-2525. | |
| |
59. Kim I.Y., Ahn H.J., Zelner D.J. et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res, 1996; 2(8): 1255-1261. | |
| |
60. Hattori K., Okamoto M., Oyasu R. Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma. Carcinogenesis, 1997; 18(10): 1867-1870. | |
| |
61. Hahn S.A., Schutte M., Hoque A.T. et al. DPC4, a condidate tumor suppressor gene at human chromosome 18q21.1. Science, 1996; 271(5247): 350-353. | |
| |
62. Thiagalingam S., Lengauer C., Leach F.S. et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet, 1996; 13(3): 343-346. | |
| |
63. Maitra A., Molberg K., Albores-Saavedra J., Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am. J. Pathol, 2000; 157(4): 1105-1111. | |
| |
64. Xu X., Brodie S.G., Yang X. et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene, 2000; 19(15): 1868-1874. | |
| |
65. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P. et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Nat. Acad. Sci. USA, 2000; 97(17): 9624-9629. | |
| |
66. Morun A., Itoh S., Moustakas A. et al. Functional cosequences of tumorigenic missense mutations in the aminoterminal domain of Smad4. Oncogene, 2000; 19(38): 4396-4404. | |
| |
67. Kleeff J., Ishiwata T., Maruyama H. et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 1999; 18(39): 5363-5372. | |
| |
68. Iolascon A., Giordani L., Borriello A. et al. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Brit. J. Cancer, 2000; 82(6): 1171-1176. | |
| |
69. Yan Z., Deng X., Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J. Biol. Chem, 2001; 276(2): 1555-1563. | |
| |
70. Sun L., Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem, 1997; 272(40): 25367-25372. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2008 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.